Translational Session
Advancing the Understanding of Proteinuria and eGFR as FSGS Clinical Trial End Points
October 25, 2024 | 04:30 PM - 06:00 PM
Location: Room 6A, Convention Center
Session Description
The kidney community has benefitted from successful clinical trials in the last decade, including newly approved therapies for people with kidney diseases. Data-sharing efforts transformed the drug development landscape for IgAN by providing a model that could be used to support the design of clinical trials and use of proteinuria as a surrogate end point and basis for approval of new treatments for IgAN. This session highlights a comprehensive international data-sharing and modeling effort across the stakeholder community intended to transform the landscape of drug development for FSGS.
Support is provided by an educational grant from Travere Therapeutics, Inc.
Learning Objective(s)
- Summarize the current landscape of clinical trials in FSGS
- Explain how to establish and measure outcomes in FSGS
- Identify innovative ways to define outcomes of FSGS in large global research networks
Learning Pathway(s)
- Glomerular Diseases
Moderators
Presentations
- Clinical Trials in FSGS: Where Have We Been and Where Are We Heading?
04:30 PM - 04:50 PM
- Regulatory Pathways, Considerations, and the Application of Previous Work in Membranous Nephropathy and IgAN to FSGS
04:50 PM - 05:10 PM
- Modeling Proteinuria and eGFR Slope as Surrogate End Points for FSGS
05:10 PM - 05:30 PM
- Panel Discussion: The Right Outcomes for Trials in FSGS
05:30 PM - 06:00 PM